The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
CH3COOH + H2O ⇌ CH3COO− + H3O+ CH3COOH + NH3 ⇌ CH3COO− + NH+4 Both theories easily describe the first reaction: CH3COOH acts as an Arrhenius acid because it acts as a source of H3O+ when dissolved in water, and it acts as a Brønsted acid by donating a proton to water. In the second example CH3COOH undergoes the same transformation, in this case donating a proton to ammonia (NH3), but does not relate to the Arrhenius definition of an acid because the reaction does not produce hydronium. Nevertheless, CH3COOH is both an Arrhenius and a Brønsted–Lowry acid. Brønsted–Lowry theory can be used to describe reactions of molecular compounds in nonaqueous solution or the gas phase. Hydrogen chloride (HCl) and ammonia combine under several different conditions to form ammonium chloride, NH4Cl. In aqueous solution HCl behaves as hydrochloric acid and exists as hydronium and chloride ions. The following reactions illustrate the limitations of Arrhenius's definition:
Each fission of uranium-235 releases an average of 2.43 neutrons, most commonly two or three. If at least one neutron from uranium-235 fission strikes another nucleus and causes it to fission, then the chain reaction will continue. If the reaction continues to sustain itself, it is said to be critical, and the mass of 235U required to produce the critical condition is said to be a critical mass. A critical chain reaction can be achieved at low concentrations of 235U if the neutrons from fission are moderated to lower their speed, since the probability for fission with slow neutrons is greater. A fission chain reaction produces intermediate mass fragments which are highly radioactive and produce further energy by their radioactive decay. Some of them produce neutrons, called delayed neutrons, which contribute to the fission chain reaction. The power output of nuclear reactors is adjusted by the location of control rods containing elements that strongly absorb neutrons, e.g., boron, cadmium, or hafnium, in the reactor core. In nuclear bombs, the reaction is uncontrolled and the large amount of energy released creates a nuclear explosion.
=== PPAR-delta agonists === PPARδ (delta) is the main target of a research chemical named GW501516. It has been shown that agonism of PPARδ changes the body's fuel preference from glucose to lipids. In August 2024, seladelpar became the first PPARδ agonist to be approved for clinical use.
Sources: en.wikipedia.org
=== Later === Many protest songs during the 1980s reflected general unease with escalating tensions between the Soviet Union and the United States brought on by Ronald Reagan's and Margaret Thatcher's hard line against the Soviets. For example, various musical artists wore military uniform-like costumes, as a reflection of the increased feeling of militarism seen in the 1980s. Songs symbolically showed the superpowers going to war, as in the Frankie Goes to Hollywood song "Two Tribes". This song's MTV music video featured caricatures of United States President Ronald Reagan and Soviet General Secretary Konstantin Chernenko in a wrestling match. Other songs expressed fear of World War III, as in the Sting song, "Russians", with lyrics such as "I don't subscribe to his [Reagan's or Khrushchev's] point of view" (that Reagan would protect Europe, or that Khrushchev would "bury" the West). Other examples include Sly Fox's "Let's go all the way", a song about "going all the way" to nuclear war, The Escape Club's "Wild, Wild West" with its various references to the Cold War and Fischer-Z's album "Red Skies over Paradise". The Genesis song "Land of Confusion" expressed a desire to make some sense out of the world, especially in relation to nuclear war. A number of punk rock bands from the 1980s attacked Cold War era politics, such as Reagan's and Thatcher's nuclear deterrence brinkmanship. A small sampling includes The Clash, Dead Kennedys, Government Issue, Fear, Suicidal Tendencies, Toxic Reasons, Reagan Youth, etc. Noted punk compilation P.E.A.C.E.
from the World Health Organization, the Paris Climate Accords, and UNESCO. The Trump administration has been criticized for its targeting of political opponents and civil society. Many of his administration's actions have been found by the judiciary to be illegal and unconstitutional, and have been criticized as authoritarian and fascistic. These actions have also been seen as contributing to democratic backsliding in the country, as well as incalculable damage to the country's international standing. Trump, his family, and his administration have faced unprecedented conflicts of interest, self-enrichment, and allegations of corruption. Trump is the first president with a felony conviction, having been convicted in 2024 for falsifying business records to conceal hush money payments. Having taken office at 78 years and seven months old, he is the oldest person to become U.S. president.
which is conservative, non-traumatic and less invasive and can be performed on an outpatient basis under local anaesthetic in a doctor's office and has the advantage of healing very quickly with little or no significant cosmetic alteration to the appearance of the penis.
=== Low-profile chains === Low-profile chains are chains with low teeth and safety elements between teeth. These chains are used on consumer and small professional saws for non-experienced operators. These chains are more insensitive against dirt, but require more frequent sharpening.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.